Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:57:19 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:MCRB - SERES THERAPEUTICS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MCRB - Q0.111.75·105.702.513.96+0.564.263.983678813.50  14.32  13.5029.98  6.5417:46:28Jan 0615 min RT 2¢

Recent Trades - Last 10 of 788
Time ETExPriceChangeVolume
17:46:28Q14.230.831
16:16:21Q13.920.523
16:10:04Q13.960.561
16:10:04Q13.960.561
16:04:03Q13.960.561
16:00:11Q13.960.561
16:00:11Q13.960.568
16:00:11Q13.960.562
16:00:11Q13.960.5611
16:00:11Q13.960.561

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-06 07:00U:MCRBNews ReleaseSeres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst(TM) Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
2025-11-24 07:00U:MCRBNews ReleaseSeres Therapeutics to Participate in Piper Sandler Healthcare Conference
2025-11-05 07:00U:MCRBNews ReleaseSeres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
2025-10-30 07:00U:MCRBNews ReleaseSeres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
2025-10-29 07:00U:MCRBNews ReleaseSeres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
2025-10-14 07:00U:MCRBNews ReleaseSeres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
2025-09-23 07:00U:MCRBNews ReleaseSeres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
2025-08-27 07:00U:MCRBNews ReleaseSeres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
2025-08-06 07:00U:MCRBNews ReleaseSeres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
2025-07-22 07:01U:MCRBNews ReleaseSeres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
2025-07-22 07:00U:MCRBNews ReleaseSeres Therapeutics Announces Leadership Transition
2025-05-27 07:00U:MCRBNews ReleaseSeres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
2025-05-07 07:00U:MCRBNews ReleaseSeres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
2025-04-29 07:00U:MCRBNews ReleaseSeres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
2025-04-23 07:00U:MCRBNews ReleaseSeres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
2025-03-13 07:00U:MCRBNews ReleaseSeres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
2025-03-04 07:00U:MCRBNews ReleaseSeres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
2025-03-03 07:00U:MCRBNews ReleaseSeres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach